...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of nephrology. >ORAMA: a study to investigate EBPG impact on renal anaemia - design and baseline data.
【24h】

ORAMA: a study to investigate EBPG impact on renal anaemia - design and baseline data.

机译：ORAMA：一项研究EBPG对肾性贫血的影响的研究-设计和基线数据。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: It is of paramount importance not only to publish anaemia management guidelines for chronic kidney disease (CKD) but also to verify their implementation in clinical practice. The Optimal Renal Anaemia Management Assessment (ORAMA) is the first European study investigating the impact of adherence to the 2004 revised European Best Practice Guidelines (EBPG) and its impact on patient outcomes. METHODS: Participating centres were randomised into 2 groups: group A with, and group B without, access to an EBPG-based computerised clinical decision support (CDS) system after baseline. Patients with stage 2-5 CKD either anaemic (haemoglobin [Hb] <11 g/dL) or treated with erythropoiesis-stimulating agents (ESAs) and/or iron supplementation were enrolled. Primary end points are based on achievement of anaemia-related guideline targets. Here, baseline data are reported descriptively. RESULTS: Fifty-three centres in 8 countries included 739 patients, 81% of whom have received dialysis. Mean baseline Hb was 11.2 g/dL, and 52% of all patients met the EBPG target of >11 g/dL Hb at baseline. However, only 37% of patients had their Hb values >11 g/dL throughout a 3-month prestudy period. Serum ferritin and transferrin saturation were above the guideline target in circa 80% of patients. The vast majority of patients (96%) received ESA therapy at baseline. CONCLUSIONS: In line with findings from previous studies ORAMA baseline data show that achievement of EBPG is suboptimal across European countries. Final results promise an insight into the impact of guideline-based CDS tools on clinical practice and target attainment.
机译：背景：至关重要的是，不仅要发布慢性肾脏病（CKD）贫血管理指南，而且要在临床实践中验证其实施。最佳肾性贫血管理评估（ORAMA）是第一项欧洲研究，研究坚持2004年修订的《欧洲最佳实践指南》（EBPG）的影响及其对患者预后的影响。方法：将参加研究的中心随机分为两组：基线后，A组可使用基于EBPG的计算机临床决策支持（CDS）系统，B组可不使用。登记患有贫血（血红蛋白[Hb] <11 g / dL）或接受红细胞生成刺激剂（ESA）和/或铁补充治疗的2-5期CKD的患者。主要终点基于与贫血相关的指导目标的实现。在此，描述性地报告了基线数据。结果：在8个国家的53个中心收录了739名患者，其中81％接受了透析。平均基线Hb为11.2 g / dL，所有患者中有52％在基线达到EBPG目标> 11 g / dL Hb。然而，在整个3个月的研究期间，只有37％的患者Hb值> 11 g / dL。在大约80％的患者中，血清铁蛋白和转铁蛋白饱和度均高于指导目标。绝大多数患者（96％）在基线时接受了ESA治疗。结论：与以前的研究结果一致，ORAMA基线数据表明，在欧洲国家，EBPG的实现不是最佳的。最终结果有望深入了解基于指南的CDS工具对临床实践和目标达成的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号